1391738-60-5

Basic information

• Product Name: tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate
• Synonyms: tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate
• CAS NO: 1391738-60-5
• Molecular Formula: C₁₁H₁₇N₃O₄
• Molecular Weight: 255.27038
• Mol File: 1391738-60-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate(1391738-60-5)
• EPA Substance Registry System: tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate(1391738-60-5)

Safety Data

• Hazardous Substances Data: 1391738-60-5(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
Tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate is utilized as a structural scaffold in medicinal chemistry for drug discovery. Its distinctive spirocycle framework offers a versatile platform for the development of novel therapeutic agents.
Used as a Reference Standard:
tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate serves as a reference standard in analytical chemistry, providing a benchmark for the assessment of purity, structure, and other properties of related compounds in research and quality control processes.
Used as an Intermediate in Organic Synthesis:
Tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.4]nonane-7-carboxylate is employed as an intermediate in various organic synthesis processes, facilitating the creation of more complex molecules and contributing to the advancement of organic chemistry.

Upstream product

• 506-87-6 ammonium carbonate 
• 101385-93-7 3-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 

Relevant articles and documents

Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design

In immunoglobulin light-chain (LC) amyloidosis, transient unfolding or unfolding and proteolysis enable aggregation of LC proteins, causing potentially fatal organ damage. A drug that kinetically stabilizes LCs could suppress aggregation; however, LC sequences are variable and have no natural ligands, hindering drug development efforts. We previously identified high-throughput screening hits that bind to a site at the interface between the two variable domains of the LC homodimer. We hypothesized that extending the stabilizers beyond this initially characterized binding site would improve affinity. Here, using protease sensitivity assays, we identified stabilizers that can be divided into four substructures. Some stabilizers exhibit nanomolar EC50 values, a 3000-fold enhancement over the screening hits. Crystal structures reveal a key π-πstacking interaction with a conserved tyrosine residue that was not utilized by the screening hits. These data provide a foundation for developing LC stabilizers with improved binding selectivity and enhanced physicochemical properties.

CD16A BINDING AGENTS AND USES THEREOF

Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.

An efficient synthesis of 1,3,7-triazaspiro[4.4]nonane-2,4-dione derivatives and antimicrobial activity thereof

Efficient methods for the synthesis of 1,3,7-triazaspiro[4.4]nonane-2,4-dione derivatives possessing an unsaturated pyrrolidine cycle have been developed affording intermediates and target compounds in high yields not requiring additional purification. Antimicrobial activity of the synthesized compounds was studied.

8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS

Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus